Chung KK, Dawson VL, Dawson TM (2003) New insights into Parkinson's
disease. J Neurol 250 [Suppl 3]:III15–III24.
Dawson TM, Dawson VL (2002) Neuroprotective and neurorestorative
strategies for Parkinson's disease. Nat Neurosci 5:1058 –1061.
Dawson TM, Dawson VL (2003a) Rare genetic mutations shed light on the
pathogenesis of Parkinson's disease. J Clin Invest 111:145–151.
Dawson TM, Dawson VL (2003b) Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819 – 822.
Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H (2003) Part II:
alpha-synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45:14 – 44.
Foltynie T, Sawcer S, Brayne C, Barker RA (2002) The genetic basis of Parkinson's disease. J Neurol Neurosurg Psychiatry 73:363–370.
Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg
MS, Shen J, Takio K, Iwatsubo T (2002) Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160 –164.
Gasser T (2001) Genetics of Parkinson's disease. J Neurol 248:833– 840.
Kato T, Katagiri T, Hirano A, Kawanami T, Sasaki H (1989) Lewy body-like
hyaline inclusions in sporadic motor neuron disease are ubiquitinated.
Acta Neuropathol (Berl) 77:391–396.
Kimura H, Kurimura M, Wada M, Kawanami T, Kurita K, Suzuki Y, Katagiri
T, Daimon M, Kayama T, Kato T (2002) Female preponderance of Parkinson's disease in Japan. Neuroepidemiology 21:292–296.
Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H,
Epplen JT, Schols L, Riess O (1998) Ala30Pro mutation in the gene en- coding alpha-synuclein in Parkinson's disease. Nat Genet 18:106 –108.
Livak KJ (1999) Allelic discrimination using fluorogenic probes and the 5
nuclease assay. Genet Anal 14:143–149.
Martin ER, Scott WK, Nance MA, Watts RL, Hubble JP, Koller WC, Lyons K,
Pahwa R, Stern MB, Colcher A, Hiner BC, Jankovic J, Ondo WG, Allen Jr
FH, Goetz CG, Small GW, Masterman D, Mastaglia F, Laing NG, Stajich
JM, Ribble RC, et al. (2001) Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA
286:2245–2250.
Moore DJ, West AB, Dawson VL, Dawson TM (2005) Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28:57– 87.
Okochi M, Walter J, Koyama A, Nakajo S, Baba M, Iwatsubo T, Meijer L,
Kahle PJ, Haass C (2000) Constitutive phosphorylation of the Parkinson's disease associated alpha-synuclein. J Biol Chem 275:390 –397.
Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, van der Brug M, Lopez de
Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D,
Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood
NW, et al. (2004) Cloning of the gene containing mutations that cause
PARK8-linked Parkinson's disease. Neuron 44:595– 600.
Perrin RJ, Payton JE, Barnett DH, Wraight CL, Woods WS, Ye L, George JM
(2003) Epitope mapping and specificity of the anti-alpha-synuclein
monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett 349:133–135.
Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B,
Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S,
Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM,
Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in
the alpha-synuclein gene identified in families with Parkinson's disease.
Science 276:2045–2047.
Pronin AN, Carman CV, Benovic JL (1998) Structure-function analysis of G
protein-coupled receptor kinase-5. Role of the carboxyl terminus in ki- nase regulation. J Biol Chem 273:31510 –31518.
